Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
135
resultados
Última actualización
31/07/2025 [06:56:00]
Resumen de: EP4592427A2
An apparatus includes a body and an actuator is coupled to the body. A needle is mounted to the actuator. The needle comprises a slot along a length to a tip. A sensor is coupled to a plurality of wires. A base is configured to be moveable by the actuator and includes a cutout, a circuit board having a microprocessor, and a plurality of contacts. Each contact is coupled to a wire of the plurality of wires. A power source is connected to the circuit board and to the base. A bracket is coupled to the bottom surface of the body and configured to receive the base. A patch is coupled to the bracket and has an adhesive. A needle is configured to be moveable by the actuator. The plurality of wires extend from the circuit board of the base, through the needle and out of the slot.
Resumen de: EP4591791A2
The present disclosure relates to a continuous glucose monitoring device. The present disclosure provides a continuous glucose monitoring device wherein: a body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus a user's additional work for attaching the body attachment unit to the body is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by the user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.
Resumen de: WO2025155053A1
The present invention relates to a laser blood collection and blood glucose measurement device. The laser blood collection and blood glucose measurement device comprises: an examinee identification unit for outputting identification information about examinees; a storage unit for storing examinee information corresponding to each piece of identification information and the laser intensity levels corresponding to the respective examinees; an operation control unit connected to the examinee identification unit and the storage unit; a capacitor module unit connected to the operation control unit and including a capacitor; and a laser output module unit that is connected to the capacitor module unit and outputs a laser of a corresponding intensity to the skin of the current examinee according to the charging voltage applied from the capacitor module unit, thereby causing bleeding. The operation control unit is connected to the examinee identification unit, identifies the examinee corresponding to the identification information applied from the examinee identification unit among the examinees stored in the storage unit and stores the examinee as the current examinee in the storage unit, determines the laser intensity level corresponding to the current examinee among the laser intensity levels stored in the storage unit, and controls the charging voltage of the capacitor according to the determined laser intensity level.
Resumen de: US2025235675A1
A monitoring system is provided. The monitoring system includes a controller and either a shunt device, an externally-communicating catheter, and/or a fluid retention device. The shunt device and catheter are configured to address fluid movement such as ascites and pleural effusions. Each of the shunt device and catheter include a plurality of sensors that communicate with the controller positioned external to a body of a subject. The plurality of sensors are configured to output a signal indicative of a total volume, a glucose amount, or an oxygenation within a fluid flowing in contact within or surrounding the shunt device or the catheter.
Resumen de: US2025235606A1
The invention discloses a closed-loop artificial pancreas insulin infusion control system, including: a detection module and an infusion module, a detection control unit is set in the detection module, an infusion control unit is set in the infusion module, and at least one calculation control unit is set in the detection module and the infusion module for calculating insulin infusion information and/or further processing of different insulin infusion information. Therefore, the closed-loop artificial pancreas insulin infusion control system can automatically switch the control unit according to different situations to avoid affecting the user experience due to the failure of a module or even bringing safety risks to the user, and to avoid replacing the whole device when only part of the function of some components fails, and to improve the utilization rate of each component of the closed-loop artificial pancreas.
Resumen de: WO2025154863A1
The present invention relates to a method for increasing the accuracy and precision of a non-invasive blood glucose measurement apparatus and, more specifically, to a method for increasing the accuracy and precision of a non-invasive blood glucose measurement apparatus, wherein, in order to increase the accuracy and precision of quantitative analysis of the non-invasive blood glucose measurement apparatus, an algorithm having a qualitative analysis and an algorithm of quantitative analysis are combined to enhance blood glucose prediction values. To this end, the present invention comprises: a step of starting measurement after making contact with the capillary system in the skin of the body by using a selected wavelength band related to blood glucose; a skin irradiation step of sequentially irradiating the blood vessels in the skin with monochromatic light corresponding to each of visible light and near-infrared light; and a detector signal step of a detector receiving signals from the monochromatic light in the skin irradiation step, wherein the detector signal step is completed, and the accuracy and precision of the non-invasive blood glucose measurement apparatus are increased.
Resumen de: WO2025154971A1
Provided is a personalized artificial intelligence-based insulin dose determination system for a terminal which can communicate with an insulin pump and a continuous blood glucose meter used by a user, the personalized artificial intelligence-based insulin dose determination system comprising: an interface layer which can communicate with the insulin pump and the continuous blood glucose meter, and signal-processes information from the insulin pump and the continuous blood glucose meter; a control layer which receives the signal-processed information from the interface layer and generates output information associated with an insulin injection amount; an outer safety layer which determines whether the output information generated from the control layer satisfies a preset threshold value condition, and if the output information satisfies the preset threshold value condition, transfers the output information to the interface layer; and a personalized safety layer which determines a safety control variable per individual by receiving, from the outside, prescription information including the total daily dose (TDD) of insulin information of a user, and transmits the determined control variable as an input variable of the control layer.
Resumen de: US2025235609A1
A closed-loop artificial pancreas insulin infusion control system is provided. The system includes a detection module configured to detect the current blood glucose level G continuously, a program module configured to preset with an rPID algorithm that converts the asymmetric blood glucose in the original physical space to the approximately symmetric blood glucose risk in the risk space and target blood glucose level, and an infusion module which is connected to and controlled by the program module and is configured to infuse insulin according to the corresponding output instructions calculated by the rPID algorithm. The simple and robust characteristics of PID algorithm can be retained, and giving the rPID algorithm the advantages of precision and flexibility, realizing precise control for closed-loop artificial pancreas insulin infusion system.
Resumen de: US2025235131A1
Disclosed are devices, systems and methods for in vivo monitoring of localized environment conditions within a patient user by measuring analytes, including glucose, oxygen, and/or other analytes. In some aspects, a sensor device includes a wafer-based substrate, at least one electrochemical sensor two-electrode contingent including a working electrode and a reference electrode on the substrate and configured to detect a target analyte in a body fluid when the sensor device is deployed within a subject's body, where the working electrode is functionalized by a chemical layer configured to facilitate a reaction involving the target analyte that produces an electrical signal; and an electronics unit in communication with the electrochemical sensor electrode contingent to transmit the electrical signal to an external processor.
Resumen de: US2025235155A1
A flexible system for utilizing data from different monitoring techniques and capable of providing assistance to patients with diabetes at several scalable levels, ranging from advice about long-term trends and prognosis to real-time automated closed-loop control (artificial pancreas). These scalable monitoring and treatment strategies are delivered by a unified system called the Diabetes Assistant (DiAs) platform. The system provides a foundation for implementation of various monitoring, advisory, and automated diabetes treatment algorithms or methods. The DiAs recommendations are tailored to the specifics of an individual patient, and to the patient risk assessment at any given moment.
Resumen de: US2025235614A1
A closed-loop artificial pancreas insulin infusion control system is provided. The system includes a detection module configured to detect the current blood glucose level G continuously, a program module connected to the detection module and preset with a hybrid artificial pancreas algorithm, used for calculating the insulin infusion amount required by the user, the hybrid artificial pancreas algorithm includes a cPID algorithm and/or a cMPC algorithm, where the input of the cPID algorithm is the intermediate value of the MPC algorithm, and the input of the cMPC algorithm is the output value of the PID algorithm, and an infusion module connected to the program module and controlled by the program module to infuse insulin according to the insulin infusion amount calculated by the hybrid artificial pancreas algorithm.
Resumen de: AU2025205069A1
MARKED-UP COPY The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between multiple applications executing on a computer, and/or encrypting data. The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between
Resumen de: AU2023420510A1
Current Type 2 Diabetes Mellitus treatments include life-style management, pharmaceuticals and may include bariatric surgery for the morbidly obese. However, issues with compliance, side effects and permanent anatomical alterations provide a need for an alternative therapy to modulate a peripheral nerve, such as the vagus nerve, in a manner that causes a plastic change in the glycemic regulatory system, with or without the involvement of the central nervous system (CNS), that changes the activity of an organ and thereby changing the activity of that organ. Low energy vagus nerve neuromodulation has potential as a new treatment for type 2 diabetes mellitus by inducing plasticity of the body's glycemic regulatory system with low energy transient stimulation. This will allow for effective use of a small implantable pulse generator that requires infrequent, or no, charging during the life of the device.
Resumen de: AU2024209583A1
The disclosure describes devices and methods for insertion and delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration. A device for delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration, may comprise: (a) a tube comprising a proximal end and a distal end, wherein the proximal end is in fluid communication with a source of the insulin or insulin analog formulation, and wherein the distal end is configured to deliver the insulin or insulin analog formulation subcutaneously; (b) a glucose sensor disposed along a central axis of the tube; and (c) a penetrating body disposed along the central axis of the tube, wherein the penetrating body comprises a cross-sectional area no more than a cross-sectional area of the glucose sensor.
Resumen de: US2025239350A1
Provided is a personalized artificial intelligence-based insulin dose determination system includes an interface layer capable of communicating with the insulin pump and the continuous blood glucose system, and signal-processing information from the insulin pump and the continuous blood glucose system, a control layer receiving the signal-processed information from the interface layer and generating output information associated with an insulin infusion amount, an outer safety layer determining whether or not the output information generated from the control layer satisfies a preset threshold condition, and delivering the output information to the interface layer when the output information satisfies the preset threshold condition, and a personalized safety layer receiving prescription information including Total Daily Dose of Insulin (TDD) information of the user from the outside to determine a personalized safety control variable, and transmitting the determined control variable as an input variable of the control layer.
Resumen de: US2025235100A1
An analyte assessment system includes an analyte sensor, a remote device, and a software application. The remote device is configured to retrieve sensor data of a patient from the analyte sensor. The software application is configured to receive an order for analyte assessment associated with an electronic medical record (EMR) of the patient, generate or retrieve a unique identifier associated with the order, authenticate the unique identifier with the remote device, activate the analyte sensor based on the unique identifier, retrieve sensor data from the remote device, generate a report, and upload the report to the EMR of the patient. Advantageously the system can streamline requests and delivery of analyte reports for third parties, reduce in-person patient interactions and time delays, reduce third party effort, increase security and integrity of patient data, update an EMR of the patient, and operate in a blinded mode for unbiased patient analyte assessment.
Resumen de: US2025235127A1
The present invention relates to a signal quality assessment system and a blood glucose level prediction system based on photoplethysmography. The signal quality assessment system comprises a near-infrared light photoplethysmography sensor, a Bluetooth module, an AI acceleration platform, and an electronic device. The AI acceleration platform serves as the central analysis unit, receiving PPG signals from the front-end sensing unit via an interface. Signal processing, including bandpass filtering composed of high-pass and low-pass filters and data normalization, is executed by the processor. Configurable AI chips are used to evaluate the quality of PPG signals, facilitating the discard of unwanted signals and subsequent reconstruction for blood glucose assessment. Processed PPG signals and the corresponding assessed blood glucose values are transmitted to a display. The display provides a comprehensive and real-time view of the monitored data, enabling efficient and timely interpretation of blood glucose values.
Resumen de: EP4588437A2
The present disclosure relates to a diabetes management system and a method for the same. The system includes a pump device and a controller, where the controller is in electrical communication with a drive system for controlling dispensation of insulin from an insulin cartridge. The controller, over a first diurnal time period, communicates electrical control signals to the drive system to cause insulin to be dispensed based on a baseline basal insulin rate that is stored. The controller also receives at least blood glucose data to control dispensation of insulin in amounts variable from the baseline basal insulin rate. Additionally, the controller modifies the baseline basal insulin rate that is stored for a second diurnal time period that is at least 20 hours after the first diurnal period, based on an amount of insulin actually dispensed during the first diurnal time period.
Resumen de: WO2024055249A1
A management device for displaying glucose information. The screen of the management device is divided into the plurality of display areas, at least comprising a first display area for displaying the status of the management device, a second display area for displaying real-time glucose information, and a third display area for displaying historical glucose concentration information. The user can intuitively and easily get the glucose information in the body.
Resumen de: CN119856162A
Systems, devices, and methods are provided for incorporating a drug delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. An integrated management system may generate a plurality of reports, which may include data related to analyte levels (e.g., glucose levels) and delivered drugs (e.g., delivered insulin). The integrated system may also include a mode in which certain types of data are no longer shared and/or stored if the user does not log in the account. The type of data shared and/or stored when the user does not log in the account may be different from the type of data shared and/or stored when the user logs in the account.
Resumen de: EP4588494A1
The invention discloses a drug delivery system with graphical user interface comprises detection device, for detecting the blood glucose level of the user; an infusion device, for infusing a drug into the user's body; and a control device, wirelessly communicated with the detection device and the infusion device, the control device controlling the drug delivery of the infusion device, and the control device provided with a graphical user interface, the graphical user interface comprising a main screen, the main screen comprising an insulin information display area and a blood glucose information display area, wherein the insulin information display area comprising insulin infusion status information, the graphical user interface displays the insulin infusion status information in a graphical and/or textual manner, to facilitate the user to intuitively know the insulin infusion status information and blood glucose information at that time.
Resumen de: US2025232078A1
Examples of a simulation framework are provided to evaluate time varying systems using a piecewise linear time invariant simulation (PLIS) approach. The simulation framework can be configured for an artificial pancreas wireless network system that controls blood glucose in Type 1 Diabetes patients with time varying properties such as physiological changes associated with psychological stress and meal patterns.
Resumen de: US2025229018A1
A drug infusion device with integrated power supply includes a drug reservoir, used for accommodating the drug to be infused, provided with a piston and a screw; a driving wheel, connected with the screw, driving the screw to push the piston forward by rotation; a power supply, used to supply power to the infusion device, including a power supply shell, a power supply cell, electrolyte and a cover plate; and a case, including an upper case and a lower case, for accommodating the drug reservoir, the drive wheel and the power supply. The power supply shell is integrated with the lower and/or the cover plate is integrated with the upper case.
Resumen de: US2025229023A1
The invention discloses a closed-loop artificial pancreas insulin infusion control system, including: detection module, an infusion module and an electronic module, the detection module, the infusion module and the electronic module all equipped with a control unit, and each control unit is preset with a first algorithm, a second algorithm and a third algorithm correspondingly. When different priority conditions are met, different modules determine the current insulin infusion information. Therefore, the closed-loop artificial pancreas insulin infusion control system can automatically switch control units according to different situations, so as to avoid affecting the user experience and even bringing security risks to users when a module set with the control unit cannot work normally.
Nº publicación: US2025229024A1 17/07/2025
Solicitante:
MEDTRONIC MINIMED INC [US]
MEDTRONIC MINIMED, INC
Resumen de: US2025229024A1
Techniques related to temporary setpoint values are disclosed. The techniques may involve causing operation of a fluid delivery device in a closed-loop mode for automatically delivering fluid based on a difference between a first setpoint value and an analyte concentration value during operation of the fluid delivery device in the closed-loop mode. Additionally, the techniques may involve obtaining a second setpoint value. The second setpoint value may be a temporary setpoint value to be used for a period of time to regulate fluid delivery, and the second setpoint value may be greater than the first setpoint value. The techniques may further involve causing operation of the fluid delivery device for automatically reducing fluid delivery for the period of time based on the second setpoint value.
BOPI
Sede Electrónica
